Palafer®

Traduzione non disponibile. Testo originale, lingua: francese.

Iron therapy. For the prevention and treatment of iron deficiency and iron deficiency anaemia. Mineral supplement. A factor in the maintenance of good health. Helps to form red blood cells and helps in their proper function. Increased iron requirements as in childhood, adolescence, and pregnancy; blood losses overt or occult. Characterized microcytic hypochromic anemia; faulty iron absorption following gastrectomy; iron loss due to menstruation, sub-clinical iron deficiencies in adolescent girls due to precarious iron balance, and geriatrics. Additional information for health care practitioner: Palafer is well tolerated by most patients, however for patients sensitive to any form of iron: one capsule once a day with a meal is recommended, or as directed by your physician. Characterized iron deficiency anemia; 24 weeks minimum. In pregnancy, one capsule daily throughout gestation. Iron supplementation in clinical cases, 12 weeks minimum. Iron poisoning is rare in adults but serious acute poisoning in children can result from ingestion of doses in excess of 1 g. Doses of 1 g should be considered as toxic in children and therapy instituted as soon as possible. Serum iron levels above 500 mcg/100 mL can be taken as presumptive evidence of poisoning; severe poisoning is usually associated with levels well above 1,000 mcg/100 mL. Symptoms may occur within about 30 minutes or may be delayed several hours. They are largely those of gastrointestinal irritation and necrosis with vomiting, diarrhea, tarry stools, hematemesis, fast and weak pulse, lethargy, low blood pressure, coma and signs of peripheral circulatory collapse. There may be a transient period of apparent recovery after 4 to 6 hours followed by a second crisis characterized by cyanosis, pulmonary edema, circulatory collapse, convulsion, and coma may then occur followed by death in 12 to 48 hours. Milk should be given immediately and vomiting induced. Eggs and milk should then be fed (to form iron-protein complexes) until it is possible to perform gastric lavage with 1% sodium bicarbonate solution (to convert the iron to a less soluble form). Gastric lavage should not be performed after the first hour of iron ingestion because of the danger of perforation due to gastric necrosis. If an iron-chelating agent such as deferoxamine mesylate is available, it should be utilized. BAL (dimercaprol) should not be used because it may form a toxic complex. Measures to combat shock, dehydration, blood loss and respiratory failure may be necessary.

Banca dati dei prodotti naturali per la salute autorizzati (BDPSNH), Health Canada: prodotti autorizzati, ingredienti, dosi, usi e avvertenze · 2024-02-07

Traduzione non disponibile. Testo originale, lingua: francese.

Contre-indications : N/A Additional information for health care practitioners: Hemosiderosis, hemochromatosis. Iron compounds are also contraindicated in the treatment of hemolytic anemias unless an iron-deficient state also exists, since storage of iron with a possible exogenous hemosiderosis can result.

Banca dati dei prodotti naturali per la salute autorizzati (BDPSNH), Health Canada: prodotti autorizzati, ingredienti, dosi, usi e avvertenze · 2024-02-07

Traduzione non disponibile. Testo originale, lingua: francese.

Précautions et mises en garde : Keep out of reach of children. This package contains enough drug to seriously harm a child. Additional information for health care practitioners: Where anemia exists, its nature should be established and underlying causes determined. Prolonged administration of iron should be avoided except in patients with continued bleeding or repeated pregnancies. In infants, large chronic doses of iron may so interfere with the assimilation of phosphorous as to cause severe rickets. Orally administered iron salts may aggravate existing disorders, such as peptic ulcer, regional enteritis and ulcerative colitis. They may not be absorbed in patients with steatorrhea and those who have had a partial gastrectomy. Before initiating parenteral iron therapy, it is advisable to give test doses to help detect sensitivity. Iron overload can occur in patients given an excess of parenteral iron, as well as those with hemoglobinopathies or other refractory anemias which might be erroneously diagnosed as iron-deficiency anemia. Do not administer oral iron preparations concomitantly with parenteral iron. Iron with tetracyclines binds in equal molecular ratio thus preventing absorption of tetracyclines. Warn patients that iron is toxic when overdoses are ingested by children. Severe reactions, including fatalities, have resulted. Concomitant administration of antacids containing aluminum and magnesium salts may impair the absorption of iron. Do not use except under the care of a physician. Consult a health care practitioner prior to use if you are pregnant or breastfeeding. Consult a health care practitioner prior to use if you have a peptic ulcer, regional enteritis or ulcerative colitis.

Banca dati dei prodotti naturali per la salute autorizzati (BDPSNH), Health Canada: prodotti autorizzati, ingredienti, dosi, usi e avvertenze · 2024-02-07

Traduzione non disponibile. Testo originale, lingua: francese.

Effets indésirables connus : Some people may experience constipation, diarrhea and/or vomiting. Additional information for health care practitioners: Oral ingestion of iron preparations may be associated with gastrointestinal discomfort (such as nausea) and dose-related bowel effects(such as constipation, diarrhea, and/or vomiting). Untoward effects usually subside with continuation of therapy or by iron ingestion with or after meals. Parenteral iron administrations can cause nausea, vomiting, and such acute allergic reactions as chills and fever, arthralgia, urticaria, and asthma. Occasional pain and staining of the skin at the site of injection may occur. Severe anaphylactoid reactions with some deaths have been reported in the literature. Although i.m. administration of iron dextran injections has caused sarcoma in laboratory animals, included malignancy in man has never been observed.

Banca dati dei prodotti naturali per la salute autorizzati (BDPSNH), Health Canada: prodotti autorizzati, ingredienti, dosi, usi e avvertenze · 2024-02-07